Dr. Jonathan Kaufman discussed treatment sequencing in relapsed/refractory multiple myeloma, noting NCCN guideline gaps and the value of triplet regimens. He highlighted CAR T therapies (Cilta-cel, Ide-cel), emphasized bridging therapy, and addressed toxicity management, especially infections.